Core Insights - CONMED Corporation (CNMD) is positioned for growth due to the rising adoption of its high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, alongside increasing robotic procedure volumes and the expansion of Ambulatory Surgery Centers (ASCs) [1][4][10] - The company is facing challenges from tariffs impacting gross margins and the launch of Intuitive Surgical's da Vinci 5, which delays AirSeal demand [2][15] Company Performance - CONMED has a market capitalization of $1.28 billion and projects a 3.4% earnings growth over the next five years, with earnings surpassing estimates in the last four quarters, averaging an 8.40% surprise [3][17] - The company reported significant progress in stabilizing its orthopedic supply chain, achieving record manufacturing volumes and reducing critical SKU shortages [11][12] Growth Drivers - Adoption of BioBrace has expanded to over 70 procedures, indicating strong surgeon uptake and versatility in soft-tissue repair applications [4] - AirSeal utilization is increasing due to its clinical benefits, while Buffalo Filter growth is supported by expanding smoke-evacuation mandates [5][10] - The expansion of robotic surgery and ASC penetration presents a meaningful growth opportunity, with incremental AirSeal utilization driven by the redeployment of Intuitive Surgical's Xi systems [6][9] Challenges - Tariffs are reducing gross margins by approximately 20 basis points in Q3, with expectations of a 150 basis point impact in Q4 [13] - The supply-chain recovery is ongoing and is expected to take one to two quarters for normalization, which may temper revenue recovery [14] - The integration of the da Vinci 5 is constraining near-term AirSeal adoption, as hospitals may not need to purchase AirSeal immediately due to the integrated insufflation system [15][16]

Core Insights - Intuitive Surgical's single-port (SP) platform is emerging as a significant growth driver, with SP procedures increasing by 91% year-over-year in Q3 2025, surpassing overall da Vinci growth and indicating strong adoption, especially outside the U.S. [1][12] Adoption and Utilization - The highest adoption rates are observed in Korea, where SP utilization has surpassed that of the legacy Xi system, indicating a shift from novelty to routine clinical use [2][12] - In the U.S., SP adoption is in its early stages, but the market is expanding with initial domestic use of the SP stapler in colorectal and thoracic procedures, which are substantial procedural categories [4][12] Clinical Evidence and Regulatory Developments - Management highlighted growing clinical evidence that SP offers patient benefits beyond cosmetic outcomes, potentially improving recovery times and length of hospital stays, which could influence adoption among surgeons and hospital administrators [3] - Regulatory momentum is crucial, with completed U.S. regulatory submissions for nipple-sparing mastectomy and other general surgery indications, aiming to replicate Korea's adoption curve in the U.S. market [5] Strategic Considerations - The key question for investors is whether SP will serve as an incremental growth driver or primarily replace multiport da Vinci volumes. Management suggests that SP's unique features may enable minimally invasive surgery in patient populations not well served by multiport systems [6] - Although SP currently contributes modestly in absolute terms, its growth trajectory indicates a potential transition from niche to mainstream, contingent on continued regulatory expansion and clinical evidence [7] Peer Updates - Stryker's robotic surgery segment showed strong momentum, achieving record Mako installations and expanding usage across various surgical cases, supported by software enhancements [8] - Globus Medical's robotics and navigation ecosystem is scaling, with the launch of ExcelsiusXR, a wearable navigation headset aimed at improving surgeon focus and ergonomics [10]

Group 1 - ICU Medical, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, with their presentation scheduled for January 14, 2026, at 1:30 p.m. PT [1] - The presentation will be available via a live webcast on the company's website, with a replay option also provided [2] - ICU Medical is recognized as a global leader in infusion systems and critical care products, focusing on quality, innovation, and value for clinical customers [3]

Core Insights - Boston Scientific's Cardiovascular segment operates in a $50 billion market, projected to grow nearly 9% from 2026 to 2028, with expectations to exceed 10% average organic revenue growth [1] - The Electrophysiology (EP) business is anticipated to grow approximately 15% over the long-range plan, driven by market share gains and expansion into new areas [1][8] - The WATCHMAN device is the leading percutaneous left atrial appendage closure (LAAC) device globally, with a long-term growth outlook of over 20% contingent on trial outcomes [2][8] - The CRM DX business is expected to grow about 4% over the long-range plan, supported by recent investments and new product launches [3] - The Interventional Cardiology Therapies (ICTx) segment is projected to achieve 10% growth, particularly in emerging markets [4][8] - The Peripheral Interventions, Interventional Oncology, and Embolics businesses collectively represent a $11 billion market, with expected growth around 7% [4] Competitive Landscape - Medtronic's Diabetes business is preparing for an IPO, while its Hugo robotic-assisted surgery system has received FDA approval for urologic procedures [5] - Johnson & Johnson has acquired Halda Therapeutics for $3.05 billion, enhancing its portfolio in prostate cancer therapies [6] Financial Performance - Boston Scientific shares have increased by 7.5% over the past year, outperforming the industry average of 1.7% [7] - The company's forward five-year Price-to-Earnings (P/E) ratio stands at 27.81, above both its median and the industry average [9] Earnings Estimates - Current earnings estimates for Boston Scientific indicate a projected earnings per share of $3.04 for the year ending December 2025, increasing to $3.45 for December 2026 [11]

Core Insights - Establishment Labs Holdings Inc. is a global medical technology company focused on enhancing women's health, particularly in breast aesthetics and reconstruction [3] - The company will present at the 44th Annual J.P Morgan Healthcare Conference on January 14, 2026, at 9:45 a.m. PT [1] Company Overview - Establishment Labs offers a range of solutions for breast health, aesthetics, and reconstruction in over 90 countries, having delivered over four million Motiva® devices since 2010 [3] - The company's product portfolio includes minimally invasive technologies such as Mia Femtech® for breast harmonization and Preservé® for breast augmentation and revision [3] - The Motiva Flora® tissue expander is the only regulatory-approved expander globally with an integrated port using radio-frequency technology, which is MRI conditional [3] - Establishment Labs has over 200 patent applications across 20 patent families and has published over 100 scientific and clinical studies in peer-reviewed journals [3] - The company operates two manufacturing facilities in Costa Rica that comply with ISO13485:2016 and FDA 21 CFR 820 standards [3]

Market Performance - US stocks gained over 8% in the third quarter of 2025, as measured by the Russell 3000 Index, with small-cap stocks rising more than 12% [1] - Large-cap stocks increased by about 8%, while mid-cap stocks saw a gain of 5% [1] Diamond Hill Mid Cap Strategy Performance - The strategy underperformed the Russell Midcap Index in Q3 2025, returning 4.49% net compared to 5.33% for the Index [1] The Cooper Companies, Inc. Overview - The Cooper Companies, Inc. (NASDAQ:COO) manufactures and markets contact lenses through its CooperVision and CooperSurgical segments [2] - The one-month return for The Cooper Companies, Inc. was 8.74%, but its shares lost 10.29% of their value over the last 52 weeks [2] - As of December 30, 2025, the stock closed at $82.47 per share, with a market capitalization of $16.396 billion [2] Investment Insights - The Diamond Hill Mid Cap Strategy initiated several new positions in Q3 2025, including The Cooper Companies, Inc. [3] - Despite the overall market rise, the company is viewed as undervalued relative to its long-term growth outlook [3] - The Cooper Companies, Inc. had consolidated revenues up 4.6% year over year to a quarterly record of $1.065 billion in Q4 2025 [4] - The number of hedge fund portfolios holding The Cooper Companies, Inc. increased from 48 to 56 in the third quarter [4]

Core Insights - Profusa, Inc. has established a new distributor partnership with MedSell in France to commercialize Lumee™ Oxygen tissue monitoring, expanding its reach in the European market [1][2] - The partnership aims to address the needs of approximately 200,000 annual Critical Limb Threatening Ischemia (CLTI) cases in the European Union, with MedSell focusing on hospital and outpatient care settings [1][2] - The collaboration with MedSell complements an existing partnership with a leading vascular surgeon in France, who accounts for about 8% of all CLTI cases in the country [2] Company Strategy - Profusa aims to achieve $200 to $250 million in revenue by 2030, with projected revenues of $0.5 to $2 million in 2026 and $9 to $13 million in 2027 [3] - The company is focused on executing its commercial strategies, including the introduction of Lumee Oxygen monitoring in Europe starting in Q2 2026, with plans to enter the US market in 2027 [3] - Profusa emphasizes the importance of making its oxygen tissue monitoring platform accessible in both clinical and home settings to enhance patient outcomes and reduce healthcare costs [3] Product Overview - Lumee Oxygen tissue monitoring is designed to measure tissue oxygen perfusion before and during surgical procedures, as well as during follow-up care, addressing a critical unmet clinical need [2] - The device is expected to provide significant value to clinicians by supporting decision-making and patient monitoring throughout the treatment pathway [2] - Profusa's technology is part of a broader initiative to develop tissue-integrated sensors that continuously transmit actionable medical data [4]

Core Insights - Shenzhen has produced a number of globally impactful companies, showcasing a shift from "Made in China" to "Created in China" [2] - The 45th anniversary of Shenzhen Special Economic Zone marks a significant milestone in its rapid modernization and brand development [2][3] - The "Shenzhen Brand Development White Paper (1980-2025)" outlines the evolution of Shenzhen's brands and their internal logic and success factors [3][5] Group 1: Brand Evolution - Shenzhen's brand journey reflects a transition from manufacturing to innovation, with key phases including the emergence of local brands in the 1980s and 1990s, and the rise of autonomous brands in the early 2000s [7][10] - The current phase is characterized by cluster upgrades, with companies like Tencent, BYD, and DJI leading in various sectors [8][10] - As of now, Shenzhen has cultivated 1,220 notable local brands, including 13 billion-level brands and 7 trillion-level brands, with Tencent, Ping An, and Huawei each exceeding a brand value of 490 billion [10][11] Group 2: Economic Contributions - The 1,220 notable brands contribute 47.97% of the city's sales, 42.05% of tax revenue, and 32.87% of exports, serving as the backbone of Shenzhen's high-quality economic development [11] - These brands span critical sectors such as electronics, renewable energy, biomedicine, high-end equipment, financial services, and digital economy, forming a robust industrial structure [11] Group 3: Brand Development Factors - Shenzhen's brand success is attributed to a unique ecosystem supported by policy innovation, technological advancement, and collaborative industrial frameworks [15][16][19] - The government has played a crucial role in creating a conducive environment for brand growth through targeted policies and regulatory frameworks [16] - Innovation drives brand competitiveness, with companies investing over 10% of their annual revenue in R&D, fostering a comprehensive innovation ecosystem [17] Group 4: Global Expansion and Responsibility - Shenzhen brands have established clear pathways for international expansion, evolving from processing trade to localized operations and global standardization [20] - Social responsibility is ingrained in the corporate strategy, enhancing brand value and sustainability through practices like tax compliance and community support [21] Group 5: Future Outlook - The release of the white paper is a significant step in documenting Shenzhen's brand journey and providing strategic guidance for future brand development [31] - Shenzhen's brands are expected to continue thriving in emerging sectors like digital and low-altitude economies, contributing to the global narrative of Chinese brands [33][34]

Core Viewpoint - The lawsuit against Inspire Medical Systems, Inc. alleges that the company made misleading statements regarding the demand and launch of its implantable medical device for obstructive sleep apnea, leading to significant financial losses for investors [1][2]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who acquired Inspire securities between August 6, 2024, and August 4, 2025 [1]. - Allegations include that the company failed to disclose poor demand for its product and had surplus inventory, which affected the transition to the new treatment [1]. - The lawsuit claims that Inspire Medical did not complete essential tasks for a successful product launch, contrary to their public assurances [1]. Group 2: Financial Impact - On August 4, 2025, Inspire Medical announced that the launch of Inspire V was delayed due to incomplete training and onboarding at treatment centers [2]. - The company admitted that software updates necessary for billing were not effective until July 1, leading many centers to continue using an earlier version of the product [2]. - Following the announcement, Inspire's stock price dropped by $42.04, or approximately 32.35%, from $129.95 to $87.91 per share [2].

Corporate Update - MedMira Inc. reported its financial results for the quarter ended October 31, 2025 [1] - The company received Health Canada approval for its Reveal® TP (Syphilis) rapid test in Q1 FY2026 [1]